Amylyx Pharmaceuticals
AMLX
147 hedge funds and large institutions have $1.51B invested in Amylyx Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 24 closing their positions.
79% more call options, than puts
Call options by funds: $56.4M | Put options by funds: $31.4M
67% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 36
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
11% more funds holding
Funds holding: 133 → 147 (+14)
3.69% more ownership
Funds ownership: 73.31% → 77% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
16% less capital invested
Capital invested by funds: $1.79B → $1.51B (-$286M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$39.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$31.3M |
| 3 |
O
OrbiMed
New York
|
+$28.3M |
| 4 |
D.E. Shaw & Co
New York
|
+$22.2M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$62.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$58.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.3M |
| 4 |
DM
Deerfield Management
New York
|
-$24.6M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$20.3M |
AMLX Hedge Fund Activity: Q1 2023 in Review
147 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2023, worth a combined $1.51B — down 16% from $1.79B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AMLX positions and 24 closed out — a net gain of 14 holders — while 60 added to existing stakes and 36 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $39.6M. The largest seller was Point72 Asset Management, cutting an estimated $62.6M.
- 147 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2023, up from 133 in Q4 2022.
- Funds reported $1.51B of Amylyx Pharmaceuticals stock for Q1 2023, down 16% quarter-over-quarter.
- 38 funds opened new Amylyx Pharmaceuticals positions in Q1 2023 and 24 closed out, a net change of +14 holders.
- The largest Amylyx Pharmaceuticals buyer in Q1 2023 was Marshall Wace, an estimated $39.6M added.
- The largest Amylyx Pharmaceuticals seller in Q1 2023 was Point72 Asset Management, an estimated $62.6M sold.
Based on aggregated 13F filings for Q1 2023.